Vitamin E
Also sold as: Alpha-tocopherol · RRR-alpha-tocopherol · All-rac-alpha-tocopherol · Tocotrienols
A family of fat-soluble compounds with antioxidant functions. Selected high-dose clinical applications exist, but prevention claims must be weighed against bleeding, prostate-cancer and mortality signals.
Longevity
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Longevity: Supplementation has not established longer life or cardiovascular protection; some high-dose analyses raise mortality concerns, and major trials report specific harms.
REALITY CHECK // Antioxidant marketing hides a difficult trade-off: selected NASH patients had improved liver histology, while high-dose prevention trials produced no general longevity benefit and specific harms. Mixed tocopherols and tocotrienols have not demonstrated superior hard clinical outcomes.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // Dossier adult ULs: EFSA 300 mg/day alpha-tocopherol and US 1000 mg/day supplemental alpha-tocopherol. Both are safety ceilings, not clinical benefit thresholds; trial harms can occur below a UL. Do not compare an IU number or total mixed-tocopherol mass directly with these mg values.
Summary
In PIVENS, 800 IU/day for 96 weeks improved histology in adults with biopsy-confirmed NASH without diabetes (43% versus 19%), without significant fibrosis improvement. This supervised disease-specific result does not justify high-dose prevention: SELECT reported increased prostate cancer, and stroke meta-analysis found more hemorrhagic strokes.
Mechanism
Alpha-tocopherol interrupts lipid oxidation chains. Hepatic alpha-TTP preferentially retains certain stereoisomers; natural and synthetic forms therefore differ in biological activity. A biochemical antioxidant role does not establish improved survival.
Typical studied dose
Disease trials used 800 IU/day for 96 weeks in PIVENS and 2000 IU/day in TEAM-AD for functional decline in Alzheimer disease. SELECT used 400 IU/day. These are high-dose clinical exposures, not routine targets. IU-to-mg conversion depends on stereochemistry and the reporting convention; this calculator accepts declared mg only.
Upper limit
Dossier adult ULs: EFSA 300 mg/day alpha-tocopherol and US 1000 mg/day supplemental alpha-tocopherol. Both are safety ceilings, not clinical benefit thresholds; trial harms can occur below a UL. Do not compare an IU number or total mixed-tocopherol mass directly with these mg values.
Popular stacks with Vitamin E
Not enough stack data yet. A combination with Vitamin E appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| RRR-alpha-tocopherol: declared alpha-tocopherol mg Best for: Comparison with the exact ingredient and dose basis on the Supplement Facts panel. |
100% elemental / active | no comparable trial range | Use already-declared alpha-tocopherol mg only. Natural RRR is preferentially retained; do not enter IU or ester/product weight. The dossier mixes IU conventions, so no numeric therapeutic mg interval is inferred. See the form-specific clinical note; tolerance depends on dose and medical context. |
Studied standard [LABEL // VERIFY_DOSE_BASIS] Use already-declared alpha-tocopherol mg only. Natural RRR is preferentially retained; do not enter IU or ester/product weight. The dossier mixes IU conventions, so no numeric therapeutic mg interval is inferred. |
| All-rac-alpha-tocopherol: declared alpha-tocopherol mg Best for: Comparison with the exact ingredient and dose basis on the Supplement Facts panel. |
100% elemental / active | no comparable trial range | Use label-declared alpha-tocopherol mg, not IU or raw acetate mass. Synthetic stereoisomers differ in retention and activity; a natural-form IU factor must not be applied to this form. No trial-matched mg interval is inferred. See the form-specific clinical note; tolerance depends on dose and medical context. |
Good option [LABEL // VERIFY_DOSE_BASIS] Use label-declared alpha-tocopherol mg, not IU or raw acetate mass. Synthetic stereoisomers differ in retention and activity; a natural-form IU factor must not be applied to this form. No trial-matched mg interval is inferred. |
| Mixed tocopherols / tocotrienols: unspecified composition Best for: Comparison with the exact ingredient and dose basis on the Supplement Facts panel. |
Unstandardized: active content unknown | no comparable trial range | Total blend mass is not equivalent to alpha-tocopherol content. Gamma/delta forms and tocotrienols have different kinetics, and no generic conversion to vitamin E IU or the alpha-tocopherol UL is defensible. See the form-specific clinical note; tolerance depends on dose and medical context. |
Caution [LABEL // VERIFY_DOSE_BASIS] Total blend mass is not equivalent to alpha-tocopherol content. Gamma/delta forms and tocotrienols have different kinetics, and no generic conversion to vitamin E IU or the alpha-tocopherol UL is defensible. |
Common label traps
- TRAP_01 // More antioxidant means longer life
Cardiovascular prevention results are negative; mortality meta-analyses conflict, with a high-dose harm signal rather than a longevity benefit. - TRAP_02 // Natural and synthetic use the same IU factor
Stereoisomer activity and reporting conventions differ. Read the declared mg and exact chemical form; do not invent a universal IU conversion. - TRAP_03 // Mixed tocopherols or tocotrienols are proven superior
Small mechanistic and clinical signals do not establish superior survival, cancer prevention or liver outcomes.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- ADULT NASH Moderate · benefit
PIVENS in non-diabetic adults: 800 IU/day for 96 weeks improved liver histology in 43% versus 19% with placebo; fibrosis did not significantly improve and survival benefit was not shown.
PMID 20427778 PMID 39412049 - PEDIATRIC NAFLD Limited · no benefit
Selected histologic signals are inconsistent; sustained ALT reduction is not reliably improved. Adult PIVENS results cannot be generalized to children.
PMID 33272889 PMID 24976277 - MORTALITY SAFETY Limited · makes it worse
The 2005 high-dose meta-analysis suggested excess mortality, about 39 additional deaths per 10000 participants in high-dose analyses. Later analyses differ; this is a safety signal, not proof every dose increases mortality. No longevity benefit established.
PMID 15537682 PMID 25398301 PMID 21235492 - STROKE SUBTYPES Moderate · makes it worse
Meta-analysis: hemorrhagic stroke RR 1.22 (95% CI 1.00–1.48); ischemic stroke RR 0.90 (0.82–0.99); total stroke RR 0.98. Opposing subtype results do not justify preventive use.
PMID 21051774 PMID 33109618 PMID 37698992 - PROSTATE CANCER Moderate · makes it worse
SELECT: 400 IU/day was associated with higher prostate-cancer incidence in initially healthy men, HR 1.17 (99% CI 1.004–1.36), about 1.6 additional cases per 1000 person-years. Catalog title is missing and requires review.
PMID 21990298 - ALZHEIMER FUNCTION Limited · benefit
TEAM-AD found slower functional decline with 2000 IU/day in mild-to-moderate disease; this is not improved everyday focus or demonstrated dementia prevention. MCI/prevention evidence remains insufficient.
PMID 24381967 PMID 28128435 - MALE FERTILITY Limited · benefit
Small heterogeneous combination trials show some semen-marker signals; MOXI findings were null. Effects cannot be assigned to E alone or translated into proven live-birth benefit.
PMID 32453396 PMID 34455507 PMID 15867002 - TOCOTRIENOLS Limited · benefit
Small vascular, liver and postmenopausal studies remain preliminary; no demonstrated superiority to alpha-tocopherol on hard endpoints.
PMID 27760402 PMID 29954374 PMID 36839192 - ORAL SKIN CLAIMS No established evidence
A lipid antioxidant mechanism does not establish scar, pigmentation or skin-rejuvenation benefit; no supporting human RCT is indexed for these claims.
Reader questions
How do I convert vitamin E IU to mg?
It depends on natural versus synthetic form and the labeling convention. Use the product-declared alpha-tocopherol mg in this calculator; do not enter IU as mg or use a universal conversion.
Does it really increase cancer or stroke risk?
SELECT found increased prostate-cancer incidence with 400 IU/day. Stroke reviews found increased hemorrhagic stroke despite a small ischemic-stroke reduction. These are clinically relevant high-dose concerns.
Can I take it with a blood thinner or before surgery?
Review it with the prescribing or surgical team. High-dose E can increase bleeding risk; this card does not supply an individualized stopping schedule.
Are tocotrienols and mixed tocopherols better?
They differ chemically and pharmacokinetically, but superior hard outcomes have not been established. Blend mass cannot be substituted for alpha-tocopherol mg.
Stack interactions
- Danger Warfarin, other vitamin K antagonists and antiplatelets [CAUTION // CLINICAL_REVIEW]
High-dose vitamin E may impair vitamin K-dependent coagulation and platelet function, increasing bleeding risk. Have the prescribing team review the combination and perioperative plan.
PMID 7121898 PMID 4479598 PMID 1099483 PMID 19401475 - Caution Vitamin K status [CAUTION // CLINICAL_REVIEW]
Vitamin K deficiency can increase concern about the coagulation effects of high-dose E; adding K is not a validated way to cancel high-dose E risk.
PMID 7121898 - Caution Oncology treatment [CAUTION // CLINICAL_REVIEW]
Possible interference with pro-oxidant cancer therapies is a precautionary mechanism, not an established interaction from a definitive RCT in this dossier. Review high-dose use with the oncology team. - Caution Other antioxidants and gamma-tocopherol [CAUTION // CLINICAL_REVIEW]
Vitamin C can regenerate tocopherol mechanistically, but no hard-outcome synergy is established. High-dose alpha-tocopherol can lower serum gamma-tocopherol; clinical meaning is uncertain.
PMID 29301023
Red flags: interactions and who should avoid it
Interactions
Warfarin, other vitamin K antagonists and antiplatelets: High-dose vitamin E may impair vitamin K-dependent coagulation and platelet function, increasing bleeding risk. Have the prescribing team review the combination and perioperative plan. Vitamin K status: Vitamin K deficiency can increase concern about the coagulation effects of high-dose E; adding K is not a validated way to cancel high-dose E risk. Oncology treatment: Possible interference with pro-oxidant cancer therapies is a precautionary mechanism, not an established interaction from a definitive RCT in this dossier. Review high-dose use with the oncology team. Other antioxidants and gamma-tocopherol: Vitamin C can regenerate tocopherol mechanistically, but no hard-outcome synergy is established. High-dose alpha-tocopherol can lower serum gamma-tocopherol; clinical meaning is uncertain.
Avoid or ask a doctor first if
Anticoagulant/antiplatelet therapy, clotting disorders, vitamin K deficiency, prior hemorrhagic stroke or planned surgery require clinical review. Avoid unsupervised high-dose use in pregnancy/lactation and prevention use in healthy men. Unexpected bruising or bleeding warrants prompt assessment.
Sources (PubMed, 9)
- Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
PMID 20427778 · 2010 · Randomized controlled trialPIVENS disease-specific histology benefit without significant fibrosis improvement.
- Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.
PMID 15537682 · 2005 · Systematic review / meta-analysisOlder high-dose meta-analysis raises an all-cause mortality safety signal.
- Vitamin E and all-cause mortality: a meta-analysis.
PMID 21235492 · 2011 · Systematic review / meta-analysisLater mortality meta-analysis provides important context to conflicting pooled findings.
- Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials.
PMID 21051774 · 2010 · Systematic review / meta-analysisQuantifies opposing hemorrhagic and ischemic stroke effects.
- Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
PMID 24381967 · 2014 · Randomized controlled trialFunctional-decline outcome in established Alzheimer disease, not healthy cognition.
- Re-evaluation of the relative potency of synthetic and natural alpha-tocopherol: experimental and clinical observations.
PMID 15219923 · 2004 · Narrative reviewReview of natural versus synthetic alpha-tocopherol relative activity.
- Biodiscrimination of alpha-tocopherol stereoisomers in humans after oral administration.
PMID 9062530 · 1997 · Randomized controlled trialHuman oral stereoisomer discrimination.
- Coagulopathy associated with vitamin E ingestion.
PMID 4479598 · 1974 · Clinical report / publication type not established in dossierClinical report of coagulopathy associated with vitamin E ingestion.
- Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review.
PMID 36839192 · 2023 · Systematic review / meta-analysisTocotrienol liver evidence remains preliminary.
Community comments
No approved comments yet. Comments are held for moderation.